An Open-label Pharmacokinetic and Tolerability Study of Teriflunomide Given as a Single 14 mg Dose in Subjects With Severe Renal Impairment, and in Matched Subjects With Normal Renal Function.

Trial Profile

An Open-label Pharmacokinetic and Tolerability Study of Teriflunomide Given as a Single 14 mg Dose in Subjects With Severe Renal Impairment, and in Matched Subjects With Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Feb 2012

At a glance

  • Drugs Colestyramine; Teriflunomide
  • Indications Hypercholesterolaemia; Multiple sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 Apr 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top